How lipid-lowering agents work: The good, the bad, and the ugly

Basit Öğe Kaydı
dc.authorscopusid15137254500
dc.authorscopusid16231562400
dc.authorscopusid57079709300
dc.contributor.authorTurgut, Faruk
dc.contributor.authorUstun, Ihsan
dc.contributor.authorGo, Cumali
dc.date.accessioned2024-09-19T15:48:44Z
dc.date.available2024-09-19T15:48:44Z
dc.date.issued2014
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractHyperlipidemia in the general population is strongly associated with atherosclerotic cardiovascular disease. Dyslipidemia is a common finding in patients with chronic kidney disease (CKD) at all stages. Trial results from the general population may not be applicable to all patients with CKD because they have a different lipid profile with increased atherogenic lipid fractions. Lipid-lowering therapies in these patients may have substantial benefit. Statin therapy is recommended in patients with CKD of any stage if they have elevated serum cholesterol levels. Treatment of dyslipidemia in patients with early stage CKD clearly reduces cardiovascular risk; however, available data do not support a strong nephroprotective role for statins in CKD population. In contrast to the predialysis patient population, statins do not seem to have substantial improvement in cardiovascular outcomes in dialysis patients. Although fibrates can be used to treat mixed dyslipidemia, they need to be used carefully in patients with CKD, and limited available data suggest that fibrates may have a place in reducing cardiovascular risk in patients with mild to moderate CKD. © Springer Science+Business Media New York 2014.en_US
dc.identifier.doi10.1007/978-1-4939-0515-7_4
dc.identifier.endpage66en_US
dc.identifier.isbn978-149390515-7
dc.identifier.isbn978-149390514-0
dc.identifier.scopus2-s2.0-84955678463en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage45en_US
dc.identifier.urihttps://doi.org/10.1007/978-1-4939-0515-7_4
dc.identifier.urihttps://hdl.handle.net/20.500.12483/15279
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSpringer New Yorken_US
dc.relation.ispartofDyslipidemias in Kidney Diseaseen_US
dc.relation.publicationcategoryKitap Bölümü - Uluslararasıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleHow lipid-lowering agents work: The good, the bad, and the uglyen_US
dc.typeBook Chapteren_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu